Investor profile
Jason Freeman
Corporate VC, Syndicate / Angel group, Venture capital & VC Investor at FundersClub, Senior Medical Director at Novartis
Jason Freeman is a Senior Medical Director at Novartis, whose known portfolio counts 16 companies.
Is Jason Freeman a fit for your startup?
Paste your website. AI checks the fit and scores every other investor too.
Investment focus
Contacts
Affiliated funds' portfolios
VC Investor at FundersClub, whose known portfolio counts 10 companies
- Fort Robotics
- Cactus
- Airweave
- Sorcerer
- Miniswap
- Quindar
- Casco
- Duranium
- Novaflow
- SubImage
Senior Medical Director at Novartis, whose known portfolio counts 16 companies
- Octave
- Vor Biopharma
- Patientory
- Orna Therapeutics
- Pliant Therapeutics
- TScan Therapeutics
- CatalYm
- Dren Bio
- Surface Oncology
- Cadent Therapeutics
- Flare Therapeutics
- Medtech Africa
- and 4 more
Investor Profile
Founders in the listed sectors AI, Commerce, Consumer and Healthcare, and focus areas Biotech, Cell & Gene Therapy, Collaboration and Computer Vision fall inside that listing.
Novartis appears in Growth, Pre-Seed and Seed rounds across its known deals.
The firm portfolio and the focus above give founders context on whether Jason Freeman matches their raise.
Colleagues
Showing 20 of 23
Paolo Malerba
Strategy Lead
London, United Kingdom
Michael Onghai
Panelist and Seed Investor
New York, United States
Justin Darcy
Angel Investment Panel Member
Denver, United States
William D Taylor IV
Angel Investor
Greenville, United States
Jeff Gorelick
Member - Investment Panel
Boston, United States
Boris S.
Co-Founder of FundersClub
San Francisco, United States
Wang Lin
Angel Investors，AI Enthusiasts，Philanthropist
Los Angeles, United States
Jose Marcilla
President Latin America and Canada (LACan) Region
United States
Beat Steffen
Managing Director Novartis Venture Fund
Basel, Switzerland
Marianne Uteng
Managing Director
Basel, Switzerland
Anja König
Global Head Novartis Venture Fund
Basel, Switzerland
Shejoy Varghese
Managing partner
Ernakulam, India
Marc Ceulemans
Head, Strategic Venture Capital Fund
Laax, Switzerland
Md. Sohel Rana
Managing Partner
Bangladesh
Steven Breazzano
Investor
Fairfield, United States
Lauren Silverman
Managing Director
Cambridge, United States
Stefanie D.
Portfolio Reporting Director
Zürich, Switzerland
Anastasia Bottos
Investor
Philadelphia, United States
Alexander Mittal
Co-Founder & CEO
San Francisco, United States
Sergey Kutsev
Investor
Russia
Frequently asked questions
Who is Jason Freeman?
Jason Freeman is a corporate venture investor and syndicate member based in Washington, District of Columbia, United States, listed as Senior Medical Director at Novartis. The known portfolio of that firm counts 16 companies. That portfolio belongs to the firm, not to Jason Freeman personally.
What does Jason Freeman invest in?
Listed sectors include AI, Commerce, Consumer and Healthcare; listed focus areas include Biotech, Cell & Gene Therapy, Collaboration and Computer Vision. Those tags come from the portfolios of the firms this profile is attached to, so they read as a record of what has been backed rather than a stated preference for what comes next.
What stage does Jason Freeman invest at?
Novartis appears in Growth, Pre-Seed and Seed rounds across its known deals, and Jason Freeman is listed there as Senior Medical Director. Stage is the strongest single filter when you build a target list: an investor with no record at your stage rarely starts with you.
Which firm is Jason Freeman listed at?
Jason Freeman is listed as Senior Medical Director at Novartis. 23 other people in the database share a firm with Jason Freeman.
How do I contact Jason Freeman?
An email address, a phone number and a LinkedIn page are on file for Jason Freeman. The address stays masked on this page and is readable inside RaiseHunt after you create an account.
Skip the browsing. Let AI find your ideal investors in one minute.
Paste your startup website and AI picks your best-fit investors out of 135,000+ profiles.
Data: RaiseHunt investor dataset · Snapshot 5 September 2026 · How this data is built · Report a correction or request removal